Imagine your alarm clock is set 90 minutes late — not because you forgot, but because the clock itself drifts. Every morning you're fighting the clock, not your willpower. That's the core model this paper proposes for a large subgroup of people with ADHD: the circadian pacemaker itself runs late, and many hallmark ADHD symptoms — inattention, impulsivity, cognitive fog — may be downstream consequences of chronic circadian misalignment rather than (or in addition to) a pure dopaminergic deficit. The numbers are striking. Up to 80% of adults and 82% of children with ADHD report insomnia or sleep disturbances. Between 73-78% show delayed sleep-wake cycles. The biological clock marker dim-light melatonin onset (DLMO) is shifted later by ~45 minutes in children and ~90 minutes in adults with ADHD versus neurotypical controls. This isn't just subjective sleepiness — it shows up in blunted morning cortisol, reduced pineal gland volume, and attenuated cycling of core clock genes BMAL1 and PER2 in peripheral tissue. The paper argues these aren't comorbidities; they're features of the same underlying chronobiological disruption. The intervention evidence, while early, is genuinely promising. A randomized trial found 0.5 mg melatonin advanced DLMO by 88 minutes in adults with ADHD, with a 14% reduction in ADHD symptoms. In children, 3-6 mg melatonin advanced DLMO by 44 minutes and added 20 minutes of total sleep. Combining melatonin with bright light therapy produced the largest phase advance (~2 hours) in adults with ADHD and delayed sleep phase. A behavioral sleep intervention trial with 244 children showed significant improvement in ADHD symptoms, sleep, quality of life, and functioning at 6 months. Critically, in a 3-week winter bright light trial, circadian preference shift — not light dose — was the strongest predictor of symptom improvement. The proposed clinical pathway is pragmatic: screen every ADHD patient for sleep and circadian disturbance, characterize chronotype with questionnaires and sleep tracking (DLMO measurement when feasible), then implement fixed wake times, morning bright light, evening light restriction, and regularized zeitgebers before considering pharmacological phase-shifting with low-dose melatonin. This behavioral-first ladder is low-risk and cheap to implement. The paper explicitly frames this as adjunctive, not replacement, therapy. Here's where honesty matters: this is a perspective piece, not a systematic review or meta-analysis. The RCTs cited are small (the largest is 244 children), many are pilot studies, and the core claim — that ADHD symptoms improve because of circadian phase correction specifically — rests on correlational evidence and a handful of trials with short follow-up windows. The children's melatonin trial showed phase advance but no change in cognitive performance or behavior at 4 weeks, though longer-term follow-up was more encouraging. The paper acknowledges these limits but its clinical recommendations outpace its evidence base somewhat. The seasonal depression connection deserves attention. The paper reports 27% of adults with ADHD meet criteria for seasonal affective disorder, and circadian disturbance significantly mediates the ADHD-seasonal depression link. If winter light deprivation worsens both circadian misalignment and ADHD symptoms through the same mechanism, bright light therapy could be hitting two birds. This is the kind of mechanistic convergence that either validates a model or reveals a confound — we don't know which yet. The biggest gap is the absence of a stratified RCT that randomizes ADHD patients to chronotherapy-first versus stimulant-first pathways and measures core ADHD outcomes over 6-12 months. Until that trial exists, the clinical pathway proposed here is a well-reasoned hypothesis with suggestive evidence, not a proven protocol. But the risk-benefit calculus is favorable: fixed wake times and morning light exposure cost nothing and harm no one, and even modest sleep improvements in ADHD populations are clinically meaningful.
